Implications of Food and Drug Administration Approval of Respiratory Syncytial Virus Prophylactic Medication.

Abstract

Therapies for prevention of respiratory syncytial virus (RSV), a major cause of lower respiratory tract infections (LRTIs) among infants and toddlers, are expanding. The Food and Drug Administration (FDA) recently approved administration of nirsevimab, a monoclonal antibody aimed at preventing medically attended RSV LRTIs, for all infants and especially those at high risk.